2018 China Montelukast Market Outlook

1
Investigation Report on China Montelukast Market,
2009-2018byChina Research and Intelligence

• Explore all reports for Life Sciences market
• _at_ http//www.chinamarketresearchreports.com/cat/li
  fe-sciences.html.

2
Investigation Report on China Montelukast Market,
2009-2018

• There are over 30 million people suffering from
  seasonal asthma of different levels worldwide,
  and the situation is worse in deeply contaminated
  countries and regions with high tobacco
  consumption. Asthma and allergic rhinitis are
  both very common diseases in the world today. As
  the atmosphere becomes more seriously
  contaminated, incidence of these diseases
  increases year by year.
• Montelukast, developed by MSD Co., Ltd., is
  widely used in curing allergic rhinitis and
  asthma. Montelukast is a CysLT1 antagonist that
  blocks the action of leukotriene D4 on the
  cysteinyl leukotriene receptor CysLT1 in the
  lungs and bronchial tubes by binding to it. This
  reduces the bronchoconstriction otherwise caused
  by the leukotriene and results in less
  inflammation.
• In 1998, montelukast sodium tablets (10mg) and
  chewable tablets (5mg) were approved by FDA to
  the market with the trade name "Singulair". In
  2000 and 2002, montelukast chewable tablets (4mg)
  and montelukast granules (4mg) were approved to
  the market in turn. They are mainly used in
  prevention and longterm treatment of asthma of
  adult and children aged two and above.
• Inquire for a discount on this report _at_
  http//www.chinamarketresearchreports.com/contacts
  /inquire-before-buy.php?name114723 .

3
Investigation Report on China Montelukast Market,
2009-2018

• Patent of Singulair in U.S. expired on August 3,
  2012. Hereafter, FDA approved over 10
  manufacturers' applications for their generic
  drugs to the market. Among them, Teva
  Pharmaceutical Industries Limited launched
  tablets, chewable tablets and oral granules while
  Dr. Reddy's Laboratories Ltd. launched tablets
  and chewable tablets. In 2012, due to the generic
  drug intrusion, sales revenue of Singulair
  produced by MSD Co., Ltd. dropped to USD 3,853
  million, decreased by 30.
• In 1999, montelukast chewable tablets (5mg) and
  tablets (10mg) produced by MSD Co., Ltd. were
  allowed to enter China with the trade name
  "Singulair". Hereafter, montelukast chewable
  tablets (4mg) and granules (4mg) were permitted
  into Chinese market sequentially. Generic
  montelukast tablets (10mg) and chewable tablets
  (5mg) produced by Sichuan Otsuka Pharmaceutical
  Co., Ltd. were approved to the market in 2006
  with the trade name "Bai Sanping". Mudanjiang
  Hengyuan Pharmaceutical Co., Ltd. was the first
  manufacturer that acquired approval of
  montelukast sodium raw material production in
  2006. In 2008, Lunan Better Pharmaceutical Co.,
  LTD. was given the approval of montelukast
  tablets (10mg) and chewable tablets (5mg)
• Complete report available _at_ http//www.chinamarket
  researchreports.com/114723.html .